Loading
Review on Lutetium-177 vipivotide tetraxetan in Prostate cancer, in Journal not given (2023), one of the most cited Europe PMC records with Lutetium-177 vipivotide tetraxetan in its title.
Europe PMC indexes no abstract for this record; the title is the only text available.
Indexed on Europe PMC as PubMed record 40209019. Its title names Lutetium-177 vipivotide tetraxetan and its text names Prostate cancer; PubMed types it as a review (Review). It was matched automatically to the idea "Alpha-emitting PSMA therapy at first metastatic diagnosis" and no figure has been checked by an editor.
One of the most cited reviews Europe PMC returns for Lutetium-177 vipivotide tetraxetan in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Total-body PET for personalised radioligand dosing.
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Total-body PET for personalised radioligand dosing.
Shares Alpha-emitting PSMA therapy at first metastatic diagnosis, Total-body PET for personalised radioligand dosing.